Infliximab, a monoclonal antibody directed against tumour necrosis factor (TNF)-α, is used in the treatment of refractory sarcoidosis. However, the clinical response is variable and a tool to select responders beforehand is highly desirable. In this study we evaluated scintigraphy with technetium-99m (99mTc)-labelled infliximab for the imaging of disease activity in patients with pulmonary sarcoidosis. 10 patients were studied using single photon emission computed tomography/computed tomography (CT) 6 h and 20 h after intravenous administration of 370 MBq of 99mTc-infliximab. Correlation analysis was performed between tissue accumulation of 99mTc-infliximab and laboratory parameters (including soluble interleukin-2 receptor and angiotensin-converting enzyme), lung function parameters (including forced expiratory volume in 1 s and the diffusing capacity of the lung for carbon monoxide) and 18Ffluorodeoxyglucose (FDG) positron emission tomography (PET)/CT. Analysis showed selective and variable accumulation of 99mTc-infliximab in the target tissue. Accumulation correlated positively with all four laboratory parameters and negatively with all four lung function parameters, yielding better correlations than serum TNF-α levels or 18F-FDG PET/CT. 99mTc-infliximab accumulation reflects the in situ TNF-α expression in an individual patient and therefore provides valuable information on the presence of the biological target for anti-TNF-α therapy.

99mTc-anti-TNF-α antibody for the imaging of disease activity in pulmonary sarcoidosis / Vis, R.; Malviya, G.; Signore, A.; Grutters, J. C.; Meek, B.; Van De Garde, E. M. W.; Keijsers, R. G. M.. - In: EUROPEAN RESPIRATORY JOURNAL. - ISSN 0903-1936. - 47:4(2016), pp. 1198-1207. [10.1183/13993003.01352-2015]

99mTc-anti-TNF-α antibody for the imaging of disease activity in pulmonary sarcoidosis

Signore A.;
2016

Abstract

Infliximab, a monoclonal antibody directed against tumour necrosis factor (TNF)-α, is used in the treatment of refractory sarcoidosis. However, the clinical response is variable and a tool to select responders beforehand is highly desirable. In this study we evaluated scintigraphy with technetium-99m (99mTc)-labelled infliximab for the imaging of disease activity in patients with pulmonary sarcoidosis. 10 patients were studied using single photon emission computed tomography/computed tomography (CT) 6 h and 20 h after intravenous administration of 370 MBq of 99mTc-infliximab. Correlation analysis was performed between tissue accumulation of 99mTc-infliximab and laboratory parameters (including soluble interleukin-2 receptor and angiotensin-converting enzyme), lung function parameters (including forced expiratory volume in 1 s and the diffusing capacity of the lung for carbon monoxide) and 18Ffluorodeoxyglucose (FDG) positron emission tomography (PET)/CT. Analysis showed selective and variable accumulation of 99mTc-infliximab in the target tissue. Accumulation correlated positively with all four laboratory parameters and negatively with all four lung function parameters, yielding better correlations than serum TNF-α levels or 18F-FDG PET/CT. 99mTc-infliximab accumulation reflects the in situ TNF-α expression in an individual patient and therefore provides valuable information on the presence of the biological target for anti-TNF-α therapy.
2016
adult; aged; female; fluorodeoxyglucose f18; humans; infliximab; male; middle aged; peptidyl-dipeptidase a; positron-emission tomography; radionuclide imaging; receptors, interleukin-2; sarcoidosis, pulmonary; single photon emission computed tomography computed tomography; technetium; tumor necrosis factor-alpha
01 Pubblicazione su rivista::01a Articolo in rivista
99mTc-anti-TNF-α antibody for the imaging of disease activity in pulmonary sarcoidosis / Vis, R.; Malviya, G.; Signore, A.; Grutters, J. C.; Meek, B.; Van De Garde, E. M. W.; Keijsers, R. G. M.. - In: EUROPEAN RESPIRATORY JOURNAL. - ISSN 0903-1936. - 47:4(2016), pp. 1198-1207. [10.1183/13993003.01352-2015]
File allegati a questo prodotto
File Dimensione Formato  
Vis_99mTc-anti-TNF-α_2016.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 445.24 kB
Formato Adobe PDF
445.24 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1413648
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 21
  • ???jsp.display-item.citation.isi??? 18
social impact